Provectus Biopharmaceuticals, Inc.
PVCT- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000315545
No open-market purchases or sales by Provectus Biopharmaceuticals, Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $8.97K in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Provectus Biopharmaceuticals, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 6 | 7 | +1 |
| Shares | 178.8K | 228.8K | +50.0K (+28.0%) |
| Value | $32.7K | $28.6K | −$4.14K (−12.7%) |
New holders (1)
Institutions that held Provectus Biopharmaceuticals, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Lee Danner & Bass Inc | 50,000 | $6.00K | 0.00% |
Sold out (0)
Institutions that held Provectus Biopharmaceuticals, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
None.